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Clinical trials in South Africa: Need for 
capacity building and training
To the Editor: The Lancet recently highlighted the importance 
of prioritising clinical research in South Africa.1 However, 
public hospitals do not encourage young medical professionals 
into clinical research. A plan to revitalise clinical research in 
South Africa is urgently needed.2
The focus of research and development (R&D) in South 
Africa is clinical trials.3 The South African Clinical Research 
Association (SACRA) estimates that in 2008 approximately 
R2.2 billion was generated through conducting internationally 
sponsored RCTs.4 This figure was limited by local regulatory 
approval times and insufficient suitable research sites. 
The Medicines Control Council (MCC) has recently made 
significant strides in reducing approval times. The deficiency in 
suitable trial sites must be addressed specifically by increasing 
capacity.
International sponsors have favoured South Africa 
for research as the population is genetically and socio-
economically diverse, relatively drug-naïve and in need of 
safe and effective therapies for a broad range of diseases.5 
Moreover, South Africa has a sound regulatory framework 
and efficient telecommunications, stipulates mandatory good 
clinical practice (GCP) training with 3 yearly updates, and is 
widely English-speaking.
The future of clinical trials depends on many factors, 
including recruitment efficiency and quality data. Despite 
recent growth in the industry, clinical research is not recognised 
as a speciality with formalised training (other than GCP), and 
proven expertise and competence is not assessed.6 Training 
programmes and certification processes must be standardised, 
with a core curriculum and reliable accreditation. Such training 
would improve investor and patient confidence and promote 
the generation of quality data. An increase in the number of 
trial sites would also increase patient recruitment potential 
and contribute towards capacity building. Such training is 
neither easily defined nor easily accessible. Internationally, a 
Masters in Public Health is regarded as the traditional degree 
for clinicians interested in research. International associations 
offering investigator certification programmes include the 
American Clinical Research Professionals (ACRP), the Society 
of Clinical Research Associates (SoCRA) and the Drug 
Information Association (DIA);7,8 however, a minimal number 
of researchers obtain such certification.
Recently, several foreign universities have been offering 
master’s degrees in clinical research, and the Royal Colleges 
of Physicians’ Faculty of Pharmaceutical Medicine offers 
a Diploma in Pharmaceutical Medicine. In South Africa, 
numerous GCP courses are offered9 and specific clinical trial-
related courses are slowly emerging. The Health Science 
Academy offers a course entitled Introduction to Clinical 
Research and another in Project Management for Clinical 
Trials. The Wits Health Consortium recently launched a quality 
control course for research sites; future courses include Starting 
Up a Research Site. Stellenbosch University offers a post-
graduate Diploma in Pharmaceutical Medicine.
Clinical research is finally starting to receive the recognition 
it deserves. For the industry to be regarded with academic 
credibility, we must generate original research in peer-reviewed 
journals. Editors have previously not been amenable to 
publishing work of this nature, but there is gradual progress in 
this area. Additionally, we need to focus on capacity-building 
conferences where we can share information with colleagues in 
the industry.
For clinical trials to grow, standardised training and 
accredited certification processes must be implemented, which 
would foster sponsor investment, promote patient confidence 
and, above all, ensure rigorous data quality and integrity – the 
cornerstone of the research industry.
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Surviving in the public sector
To the Editor: I have read the latest Med-e-Mails from SAMA 
with increasing distress. The apparent failure of our new 
Minister of Health to solve the problem of enabling doctors to 
negotiate just salary increases, because of labour legislation, 
is sad indeed. The obvious anger that this has evoked among 
members of the profession is very serious. It is awful to 
hear threats of resorting to strike action once more in this 
essential service. We can expect that the brain drain will again 
accelerate.  Medical and nursing staff who decide to stay in 
the service for love of our people will be increasingly open to 
burn-out and discouragement.  
My experience of 48 years in the public health structures of 
this nation suggests that those who stay will not find help in 
coping from the Department of Health. Those sensitive to their 
neighbours’ pain then often find the situation intolerable – they 
have to opt out for their own well-being. My own experience 
of that, as a gynaecologist in a rural KZN town, came in 2001. 
Dealing with as many as 120 child rapes per annum over a 
period of 10 years upset me so much that I had to pass this 
important and difficult work on to more junior staff with less 
experience. Now, with more time to consider the problem, I 
realise that medical staff in public hospitals must take care 
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